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ÖZET
Amaç: Bu çalışmada, tekrarlayan düşük nedeni ile hema-
toloji polikliniğine başvuran ve en az bir trombofilik defekt 
saptanan kadınlarda trombofilik risk faktörleri ve sıklığını 
değerlendirmek amaçlanmıştır.
Gereç ve yöntem: Bir ya da daha fazla trombofilik defekt 
(protein S eksikliği, protein C eksikliği, antitrombin, aktive 
protein C direnci (APC-R), faktör V Leiden (FVL), protrom-
bin G 20210A (PTG), metilentetrahidrofolat redüktaz (MT-
HFR C677 T) gen mutasyonları, antifosfolipid antikorları 
(antikardiyolipin antikoru IgM ve IgG, lupus antikoagülanı) 
varlığı ve Faktör VIII yüksekliği) ve tekrarlayan abortus 
öyküsü olan 41 olgu geriye dönük olarak araştırıldı.
Bulgular: En sık saptanan trombofilik defekt %53.7 MT-
HFR 677T mutasyonu idi. Kırk bir hastanın 22’si (%53.7) 
(n:22; 20 ikili, 2 üçlü defekt) birden fazla defekti aynı anda 
birlikte taşımaktayken, 20’si aynı anda iki, geri kalanı üçlü 
defekte sahipti.
Sonuç: Hasta grubumuzda MTHFR gen mutasyonu tek 
ve/veya diğer trombofilik faktörlerle kombine olarak, tek-
rarlayan abortuslu hastalarda en sık rastlanan herediter 
trombofili etkeni olarak saptandı. Klin Den Ar Derg 2010; 
1(3): 168-172
Anahtar  kelimeler:  trombofili;  klinik  trombofili,  tekrar-
layan abortus, factör V Leiden gene mutasyonu, aktive 
protein-C direnci, metilentetrahidrofolat redüktaz gen mu-
tasyonu, protrombin G20210A gen mutasyonu, protein C 
eksikliği, protein S eksikliği, antikardiolipin antikor, lupus 
antikoagülanı
ABSTRACT
Objectives: The aim of this study was to determine the 
thrombophilic  risk  factors  and  their  frequency  among 
women with history of recurrent abortion and a detected 
thrombophilic defect.
Materials and methods: In this study, 41 women with 
history of recurrent abortion, who have one or more de-
tected thrombophilic defects including protein S, protein 
C, antithrombin deficiency, activated protein C resistance 
(APC-R), factor V Leiden (FVL), prothrombin G 20210A 
(PTG),  methylenetetrahydrofolate  reductase  (MTHFR) 
C677 T gene mutation, antiphospholipid antibodies and 
elevated levels of factor VIII were retrospectively inves-
tigated.
Results: The most common detected thrombophilia de-
fect (53.7%) was MTHFR gene mutation. While 22 of 41 
patients (53.7%) had more than one concomitant defect, 
20 of them had two concomitant defects and the remain-
ing had three defects.
Conclusion: MTHFR gene mutation, alone and/or with, 
concurrent thrombophilic defects was the most frequent 
factor  for  hereditary  thrombophilia  among  our  patients 
with a history of recurrent abortion. J Clin Exp Invest 2010; 
1(3): 168-172
Key words: thrombophilia; clinical thrombophilia, recur-
rent abortion, factor V Leiden gene mutation, actived pro-
tein-C  resistance,  methylenetetrahydrofolate  reductase 
gene  mutation,  prothrombin  G20210A  gene  mutation, 
protein C deficiency, protein S deficiency; anticardiolipin 
antibody, lupus anticoagulantO. Yokuş et al. Thrombophilic risk factors in recurrent abortion 169
J Clin Exp Invest   www.clinexpinvest.org   Vol 1, No 3, December 2010
INTRODUCTION
Thrombophilia  is  defined  as  a  predisposition  to 
thrombosis because of disturbances in hemostatic 
mechanisms.  It  may  originate  from  hereditary  or 
acquired  causes.1  Disturbances  of  anticoagulant 
mechanisms that occur during pregnancy can cause 
thrombophilia. This can result in placental insuffi-
ciency and abortus.2-8
Recurrent abortion is the condition that defined 
as three or more spontaneous consecutive miscar-
riages at a gestational age of 20 weeks or less. The 
frequency of recurrent abortion is about 0.5-1% per 
100  pregnancy.9  While  the  females  having  preg-
nancy complications were detected to have throm-
bophilic defects in a ratio of 49-65%, this frequency 
was  found  about  18-22%  in  normal  pregnancies. 
This make people think that complication risk in-
creases by 3-8 fold, based on thrombophilia.3,10,11
Increased early and late miscarriage risk for fe-
males with thrombophilic defects has been report-
ed.12 Thrombophilia screening tests should be done 
in  cases  with  venous  thromboembolism  occurred 
during pregnancy or puerperium, first and second 
trimester miscarriages and intrauterine fetal death, 
however, routine screening is not advised for all 
pregnancies. 13 It is well known that the frequency 
of thrombophilic defects would differ among dis-
tinct societies.
The  aim  of  this  study  was  to  determine  the 
thrombophilic risk factors and their frequency in 
women that presented to the hematology outpatient 
clinics with recurrent abortion history and at least 
one detected thrombophilic defect.
MATERIALS AND METHODS
Forty one women that presented with a history of re-
current abortus and found to have at least one throm-
bophilic defect during examination were evaluated 
retrospectively. Patients admitted with spontaneous 
abortion without any thrombophilic risk factor were 
not included in the study. Demographic and clinical 
characteristics of the study group are summarized 
in Table 1.Written informed consent was obtained 
from all patients before drawing the blood samples. 
The study was carried out in accordance with the 
Helsinki Declaration.
Patients with oral contraceptive usage and hor-
mone replacement therapy, with prior surgical in-
tervention history of recent date and patients with 
a  diagnosis  of  myeloproliferative  disease,  parox-
ysmal  nocturnal  hemoglobinuria  (PNH),  diabetes 
mellitus, dyslipidemia, chronic liver disease, ma-
lignancy, vasculitis, collagenous tissue disease and 
central venous catheter thrombosis were excluded 
from the study. Laboratory tests related to throm-
bophilia were performed at least 3 months after a 
thrombotic event, at least 15 days after discontinua-
tion of heparin therapy or its derivatives and at least 
4 weeks after discontinuation of warfarine deriva-
tives. Positive results were repeated at least once 
again. No the patients were pregnant at the time of 
laboratory studies.
In this study, we evaluate antithrombin (AT) ac-
tivity, protein C (PC) activity, total and free protein 
S (PS) antigen and activity, activated protein C re-
sistance, factor V Leiden (FVL) G1691A gene mu-
tation, prothrombin 20210A (PTG) gene mutation, 
methylenetetrahydrofolate  reductase  (MTHFR) 
C677T gene mutation, factor VIII (F VIII) levels and 
antiphospholipid antibodies including APA, anticar-
diolipin antibodies (ACA) IgG and ACA IgM and 
finally lupus anticoagulant. Commercial PCR kits 
(MTHFR LC PCR, QIAGEN) were used to inves-
tigate MTHFR C677T gene mutations. Prothrom-
bin G20210A gene mutations and FVL mutations 
were also detected by using commercial kits (Roche 
Diagnostics). We used “LightCycler 1.5” ROCHE” 
real  time  PCR  device  in  our  study.  Twelve-hour 
fasting needed for venous blood sampling and cit-
rated blood specimens were centrifuged at 1500 x g 
for 15 minutes to measure AT, PC, PS, APC-R, LA, 
FVIII levels. Citrated samples were stored at -20C 
while waiting. PC activity, PS activity, AT activity 
and FVIII levels were examined by commercial kits 
(Dade Behring) and APC-R was assessed by a Dade 
Behring proC global kit. BCS instrument (Dade-
Behring) was used for test analyses. Cut-off values 
were determined by a laboratory reference range 
study on 40 healthy individuals and the following 
ranges were accepted to be normal: 70-140% for 
protein C activity, 58-127% for protein S activity, 
75-125% for AT activity and 70-150% for FVIII 
activity.  Patients  with  high  levels  of APTT  were 
examined by LA-sensitive aPTT reagent PTT-LA 
(Diagnostica Stago) test. Presence of heparin, dys-
fibrinogenemia, factor inhibitors, intrinsic pathway O. Yokuş et al. Thrombophilic risk factors in recurrent abortion 170
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factor deficiencies were excluded. The plasma clot-
ting time increases in the presence of LA. Differ-
ence of 8 seconds between the two clotting times 
was  accepted to  be  positive for  LA.  Diagnostica 
Stago  STart  4  Hemostasis Analyzer  (Diagnostica 
Stago, France) was used for these analyses. Com-
mercial Intec cardiolipin IgM and IgG l ELISA kits 
were used to detect ACA IgM and ACA IgG lev-
els on a Biomaster instrument. Values less than 2.0 
PL-U/ml were accepted to be normal for ACA IgM 
and ACA IgG. Values more than 12 PL-U/ml for at 
least two separate measurements was considered to 
be positive.
Statistical analyses
SPSS 13.0 for Windows Statistical Software Pack-
age was used to analyze the data. The descriptive 
statistics including mean ± standard deviation were 
used for continuous variables and number and per-
cents of categorical variables.
RESULTS
A thrombosis history was documented in 17.1% of 
the patients (n=7) before the study. Family history 
for thrombosis was positive for only one patient. 
The most frequently detected thrombophilic defect 
was MTHFR 677T gene mutation with a percentage 
of %53.7 (n=22; 15 heterozygote, 7 homozygote). 
This ratio was followed by FVL gene mutation with 
a percentage of 39% (n= 16; 14 heterozygote, 2 
homozygote) and PS deficiency with a percentage 
of19.5% (n= 8). The ratio of patients having more 
than one concurrent defects (n=22) was 53.7%; 20 
of them had two, while the remaining had 3 concur-
rent  defects.  Detected  concomitant  thrombophilic 
defects in our study group presented with a history 
of recurrent abortion and their frequency are shown 
in the Table 1.
DISCUSSION
Hereditary thrombophilia may cause infarcts sec-
ondary  to  placental  vascular  thrombosis  that  re-
sults in recurrent miscarriages and intrauterine fetal 
death.14 In our study, as well as PC, PS, AT activity 
deficiency, FVL gene mutation, APC-R, PTG and 
MTHFR gene mutation; the presence of anticardi-
olipin antibodies and LA tests were also done for 
hereditary thrombophilia screening. Homocysteine 
levels were ruled out of the study because it is af-
fected by too many acquired factors and nutritional 
status of the patient.
Existing  studies  showed  that  FVL  gene  and 
PTG mutations were the most frequent risk factors 
among patients with recurrent fetal loss. Investiga-
tion of these two mutations primarily in patients 
with recurrent miscarriages of unknown origin have 
been recommended. Also it was reported that FVL 
gene mutation and PT gene mutation were the most 
frequent defects that may be together. The ratio for 
concomitance of two defects was found as 17.6% in 
our study and this ratio was higher than the previ-
ously reported ratios for normal population.15
In a previous study, it was shown that concom-
itance of two or more defects together and/or ho-
mozygosity of the mutation effects pregnancy more 
unfavorably, compared to the presence of single he-
reditary thrombophilic factor.16 Among our patients, 
the most frequently observed concomitant defects 
were  MTHFR  and  FVL  gene  mutation. Whereas 
double defects ratio was found to be 48.8%, the to-
tal ratio for combined defects was found as 53.7% 
in our study. Increase of this ratio may be based on 
the fact that the patients with at least one thrombo-
philic defect were included in the study. Occurrence 
of more than one defect concomitantly for approxi-
mately half of the patients in our study is compatible 
with this literature data. The results of investigations 
about whether MTHFR gene mutation increases the 
risk for recurrent abortion is still controversial.17,18 
Whereas the ratio of MTHFR C677T gene mutation 
among patients with a history of recurrent abortion 
has been found as 30%, while it was 7% for control 
group.19 This data is in concordance with the find-
ings of our study that indicate high levels of MTH-
FR gene mutation. In that study, it was shown that 
MTHFR gene mutation was related to early and late 
complications of pregnancy.19
Limitation of our study was the lack of control 
group consisting of healthy subjects had the history 
of normal pregnancy and the patients presented with 
recurrent abortus without thrombophilic risk factor.
In conclusion, MTHFR gene mutation may be 
the most frequent hereditary thrombophilic factor 
among patients with a history of recurrent abortion 
in women. It can be suggested that the patients who 
are presented to hematology outpatient clinics in 
order to be examined about the etiology of recur-O. Yokuş et al. Thrombophilic risk factors in recurrent abortion 171
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rent abortion, must be investigated primarily about 
the  most  frequent  thrombophilic  defects-MTHFR 
and FVL gene mutations- and about the presence of 
anticardiolipin antibodies (and/or Lupus anticoagu-
lant) as it may cause several complications during 
pregnancy.
Table 1. Demographic and clinical characteristics of the study group
Patients (n) 41
Age, median range (min-max)* years 31 (20-45)
Live births, median range (min-max)* (n) 1 (0-5)
Miscarriages, median range (min-max)* (n) 3 (3-14)
Other pregnancy complications (n=4) preeclampsia (n=3), intrauterine fetal death (n=1) 
Previous treatment modalities warfarin (n=4, for previous IS and PE)
Thrombosis history (n=7) IS (n=3), DVT (n=3), PE (n=1)
APS n=3
*: minimum-maximum, IS: ischemic stroke, PE: pulmonary embolism, DVT: deep venous thromboses, APS: antiphos-
pholipid syndrome
Table 2. The frequency of single and concomitant thrombophilic defects detected in cases with recurrent abortion
MTHFR: 53.7% (n= 22; 15 heterozygotes, 7 homozygotes)
FVL: 39% (n= 16; 14 heterozygotes, 2 homozygotes)
PS: 19.5% (n= 8)
Thrombophilic defects (n= 41) APA: 14.6% (n= 6)
PTG: 12.2% (n= 5; 3 heterozygotes, 2 homozygotes)
FVIII: 9.8% (n= 4)
PC: 4.9% (n= 2)
A-PCR: 4.9% (n= 2)
Single thrombophilic defect: 19 (46.3%)
Two defects: 20 (48.8%)
Three defects: 2 (4.9%)
Concomitant thrombophilic defects (%)
The most common is MTHFR: 31.7(n= 13) MTHFR+PS+APA (n=1), MTHFR+PS+FVL (n=1)
Second common is FVL: 26.8 (n= 11) MTHFR+FVL (n= 4), MTHFR+FVIII (n= 2), MTHFR+APA (n=2), MTHFR+PS (n=3),
Third common is PS: 17(n=7)
PTG+FVL(n:4), PTG+FVIII (n=1), PC+FVIII (n=1), PC+FVL(n=1), PS+FVL (n=1),
PS+APC-R (n=1)
FVL: Factor V Leiden G1691A gene mutation; MTHFR: 5,10-methylenetetrahydrofolate reductase C677T gene mu-
tation; PTG: Prothrombin G20210A gene mutation; PC: protein C deficiency; PS:protein S deficiency; FVIII: Elevated 
factor VIII levels; APA: Antiphospholipid antibody (anticardiolipin antibody IgG , IgM and lupus anticoagulant), APC-R: 
Actived protein-C resistance without FVL gene mutationO. Yokuş et al. Thrombophilic risk factors in recurrent abortion 172
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